A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

Published

Khoo, J. K., Montgomery, A. B., Otto, K. L., Surber, M., Faggian, J., Lickliter, J. D., Glaspole, I. (2019).

Journal of aerosol medicine and pulmonary drug delivery, 32(0), 1-6.
 

Read the publication

Back to overview